Donald Williams was appointed to the Board in March 2017 and serves on Audit and Risk Management and Nomination Committees.
Don has more than 35 years of experience providing strategic guidance and operational oversight as a Certified Public Accountant (CPA) and an accredited public company director. Don has significant experience assisting companies and management teams with initial public offerings, complex business challenges and analysis of financial repoting matters. His breadth of experience includes a diverse set of growing domestic and international companies including – venture financings, public equity offerings, and interaction with the US Securities and Exchange Commision and Public Company Accounting Oversight Board.
While at both Ernst & Young and Grant Thornton, Don was focused on the Life Sciences Industry. For over 15 years, he directed Ernst & Young’s Venture Capital and Emerging Growth Markets in the Southeast Market and in the Pacific Southwest Market. During his seven years at Grant Thornton he was the National Leader of the United States Life Sciences Industry. His oversight if the National Life Sciences Industry included setting strategy, establishing the sales and marketing plan and oversight of industry operations.
|COMPANY NAME||APPOINTED||RETIRED / RESIGNED|
|ImpediMed Limited||March 17||–|
|Akari Therapeutics (i)||June 16||–|
|Alphatec Holdings Inc (i)||May 15||–|
|Marina Biotech Inc (i)||September 14||–|
(i) US-based publicly traded company.